Neumora Therapeutics, Inc. (NMRA) Stock Forecast & Price Target

Compare

365 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

NMRA Analyst Ratings

Moderate Buy

6 Buy

2 Hold

1 Sell

Based on 9 analysts giving stock ratings to

Neumora

Therapeutics, Inc.

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

NMRA Stock 12 Month Forecast

Average Price Target

$9.14

▲(311.71% Upside)

Based on 9 Wall Street analysts offering 12 month price targets for Neumora Therapeutics, Inc. in the last 3 months. The average price target is $9.14 with a high forecast of $18.00 and a low forecast of $3.00. The average price target represents a 311.71% change from the last price of $2.22.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","9":"$9","14":"$14","19":"$19","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$18.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9.14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$9.14</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,4,9,14,19],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.79,3.036923076923077,4.283846153846154,5.530769230769231,6.777692307692308,8.024615384615384,9.271538461538462,10.51846153846154,11.765384615384615,13.012307692307694,14.259230769230768,15.506153846153847,16.753076923076925,{"y":18,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.79,2.355384615384615,2.920769230769231,3.4861538461538464,4.0515384615384615,4.616923076923077,5.182307692307692,5.747692307692308,6.313076923076923,6.878461538461538,7.443846153846153,8.009230769230768,8.574615384615385,{"y":9.14,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.79,1.883076923076923,1.9761538461538461,2.0692307692307694,2.1623076923076923,2.2553846153846155,2.3484615384615384,2.4415384615384617,2.5346153846153845,2.6276923076923078,2.7207692307692306,2.813846153846154,2.9069230769230767,{"y":3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":10.6,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.93,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.56,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.91,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.77,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.75,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.8,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.56,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.74,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.78,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.02,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.42,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.79,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$18.00

Average Price Target$9.14

Lowest Price Target$3.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Myles Minter

William Blair

Hold

―

Reiterated

01/13/26

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD), Apellis Pharmaceuticals (NASDAQ: APLS) and Neumora Therapeutics, Inc. (NASDAQ: NMRA)

Marc Goodman

Leerink Partners

Buy

260.36%

Upside

Initiated

01/11/26

Diversified CNS Pipeline and NLRP3 Opportunity Drive Upside in Neumora: Justifying an Outperform/Buy Rating

Ami Fadia

Needham

Buy

260.36%

Upside

Reiterated

01/05/26

Analysts Offer Insights on Healthcare Companies: PTC Therapeutics (NASDAQ: PTCT), Neumora Therapeutics, Inc. (NASDAQ: NMRA) and Arcellx Inc (NASDAQ: ACLX)

Douglas Tsao

H.C. Wainwright

$18

Buy

710.81%

Upside

Reiterated

01/05/26

Positive Risk-Reward on Neumora as NMRA-511 Emerges as a Differentiated Therapy for Alzheimer’s Agitation, Supporting Buy Rating and $18 Target

Graig Suvannavejh

Mizuho Securities

$5→$6

Buy

170.27%

Upside

Reiterated

01/05/26

Analysts Are Bullish on These Healthcare Stocks: Fortrea Holdings Inc. (FTRE), DENTSPLY SIRONA (XRAY)

Tessa Romero

J.P. Morgan

Sell

―

Reiterated

01/05/26

J.P. Morgan Remains a Sell on Neumora Therapeutics, Inc. (NMRA)

Brian Abrahams

RBC Capital

$4→$7

Buy

215.32%

Upside

Upgraded

12/01/25

Neumora Therapeutics upgraded to Outperform from Sector Perform at RBC CapitalNeumora Therapeutics upgraded to Outperform from Sector Perform at RBC Capital

Paul Matteis

Stifel Nicolaus

$2→$3

Hold

35.14%

Upside

Reiterated

11/17/25

Neumora Therapeutics, Inc. (NMRA) Gets a Hold from Stifel Nicolaus

Yatin Suneja

Guggenheim

$14

Buy

530.63%

Upside

Upgraded

10/27/25

Guggenheim upgrades Neumora Therapeutics, Inc. (NMRA) to a Buy

Tazeen Ahmad

Bank of America Securities

Sell

-54.95%

Downside

Downgraded

04/01/25

Neumora Therapeutics, Inc. Faces Setbacks with Delayed MDD Program and Discontinued Bipolar Depression Study

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Myles Minter

William Blair

Hold

―

Reiterated

01/13/26

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD), Apellis Pharmaceuticals (NASDAQ: APLS) and Neumora Therapeutics, Inc. (NASDAQ: NMRA)

Marc Goodman

Leerink Partners

Buy

260.36%

Upside

Initiated

01/11/26

Diversified CNS Pipeline and NLRP3 Opportunity Drive Upside in Neumora: Justifying an Outperform/Buy Rating

Ami Fadia

Needham

Buy

260.36%

Upside

Reiterated

01/05/26

Analysts Offer Insights on Healthcare Companies: PTC Therapeutics (NASDAQ: PTCT), Neumora Therapeutics, Inc. (NASDAQ: NMRA) and Arcellx Inc (NASDAQ: ACLX)

Douglas Tsao

H.C. Wainwright

$18

Buy

710.81%

Upside

Reiterated

01/05/26

Positive Risk-Reward on Neumora as NMRA-511 Emerges as a Differentiated Therapy for Alzheimer’s Agitation, Supporting Buy Rating and $18 Target

Graig Suvannavejh

Mizuho Securities

$5→$6

Buy

170.27%

Upside

Reiterated

01/05/26

Analysts Are Bullish on These Healthcare Stocks: Fortrea Holdings Inc. (FTRE), DENTSPLY SIRONA (XRAY)

Tessa Romero

J.P. Morgan

Sell

―

Reiterated

01/05/26

J.P. Morgan Remains a Sell on Neumora Therapeutics, Inc. (NMRA)

Brian Abrahams

RBC Capital

$4→$7

Buy

215.32%

Upside

Upgraded

12/01/25

Neumora Therapeutics upgraded to Outperform from Sector Perform at RBC CapitalNeumora Therapeutics upgraded to Outperform from Sector Perform at RBC Capital

Paul Matteis

Stifel Nicolaus

$2→$3

Hold

35.14%

Upside

Reiterated

11/17/25

Neumora Therapeutics, Inc. (NMRA) Gets a Hold from Stifel Nicolaus

Yatin Suneja

Guggenheim

$14

Buy

530.63%

Upside

Upgraded

10/27/25

Guggenheim upgrades Neumora Therapeutics, Inc. (NMRA) to a Buy

Tazeen Ahmad

Bank of America Securities

Sell

-54.95%

Downside

Downgraded

04/01/25

Neumora Therapeutics, Inc. Faces Setbacks with Delayed MDD Program and Discontinued Bipolar Depression Study

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Neumora Therapeutics, Inc.

3 Months

xxx

Success Rate

5/10 ratings generated profit

Average Return

-9.95%

upgraded a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of -9.95% per trade.

1 Year

Douglas TsaoH.C. Wainwright

Success Rate

8/14 ratings generated profit

Average Return

+32.58%

reiterated a buy rating 10 days ago

Copying Douglas Tsao's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +32.58% per trade.

2 Years

xxx

Success Rate

9/14 ratings generated profit

Average Return

+34.77%

reiterated a xxx

rating 10 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 64.29% of your transactions generating a profit, with an average return of +34.77% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NMRA Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, NMRA has received 9 Buy Ratings, 5 Hold Ratings, and 1 Sell Ratings. NMRA average Analyst price target in the past 3 months is 9.14.

Each month's total comprises the sum of three months' worth of ratings.

NMRA Financial Forecast

NMRA Earnings Forecast

Next quarter’s earnings estimate for NMRA is -$0.33 with a range of -$0.37 to -$0.25. The previous quarter’s EPS was -$0.35. NMRA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year NMRA has Performed in-line its overall industry.

No data currently available

NMRA Sales Forecast

Next quarter’s sales forecast for NMRA is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. NMRA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year NMRA has Performed in-line its overall industry.

NMRA Stock Forecast FAQ

What is NMRA’s average 12-month price target, according to analysts?

Based on analyst ratings, Neumora Therapeutics, Inc.’s 12-month average price target is 9.14.

What is NMRA’s upside potential, based on the analysts’ average price target?

Neumora Therapeutics, Inc. has 311.71% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is NMRA a Buy, Sell or Hold?

Neumora Therapeutics, Inc. has a consensus rating of Moderate Buy which is based on 6 buy ratings, 2 hold ratings and 1 sell ratings.

What is Neumora Therapeutics, Inc.’s price target?

The average price target for Neumora Therapeutics, Inc. is 9.14. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $18.00 ,the lowest forecast is $3.00. The average price target represents 311.71% Increase from the current price of $2.22.

What do analysts say about Neumora Therapeutics, Inc.?

Neumora Therapeutics, Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of NMRA?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Neumora Therapeutics, Inc. (NMRA) Stock Forecast & Price Target

NMRA Analyst Ratings

NMRA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Neumora Therapeutics, Inc.

NMRA Analyst Recommendation Trends

NMRA Financial Forecast

NMRA Earnings Forecast

NMRA Sales Forecast

NMRA Stock Forecast FAQ

Detailed List of Analyst Forecasts